Abstract CN13-03: Intraductal route of breast cancer prevention and therapy: from preclinical studies to Phase I trials

CN13-03 We hypothesized that it is possible to prevent and treat breast cancer by accessing the mammary ductal network through the teat. This intraductal approach, which delivers a high dose of drug locally to the tumors but a low dose systemically, could be an alternative approach to therapy and prevention of breast cancer. Our previous work has demonstrated the effectiveness of intraductal administration of pegylated liposomal doxorubicin, (PLD) and 4-hydroxytamoxifen (4-OHT) using the rat N-methyl N’-nitrosourea (MNU)-induced and the spontaneous, HER2/neu transgenic mouse (neu-N) models of breast cancer. 4-OHT had a preventive effect in the rat MNU-induced models, and PLD had a preventive and therapeutic effect in both the rat and Her2/neu transgenic mouse models (Murata et al, Cancer Res. 2006). Recently we evaluated the effectiveness of other drugs such as carboplatin, methotrexate, Abraxane, 5-Fluorouracil and PLD by whole mount analysis of the treated mammary glands, histopathology following HE1(7 Suppl):CN13-03.